|
Bare Lymphocyte Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Both the p41 and p36 subunits were absent in immunoprecipitations of RFX5 from lysates of independently established B cell lines from bare lymphocyte syndrome complementation groups B and D. Together, these results suggest that RFX complex assembly is required for class II expression and that the mutations in bare lymphocyte syndrome complementation groups B and D result in an inability to assemble the RFX complex.
|
9190936 |
1997 |
|
Bare lymphocyte syndrome 2
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Both the p41 and p36 subunits were absent in immunoprecipitations of RFX5 from lysates of independently established B cell lines from bare lymphocyte syndrome complementation groups B and D. Together, these results suggest that RFX complex assembly is required for class II expression and that the mutations in bare lymphocyte syndrome complementation groups B and D result in an inability to assemble the RFX complex.
|
9190936 |
1997 |
|
Brain Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Loss of heterozygosity (LOH) involving the distal chromosome 1 p36 region occurs frequently in nonastrocytic brain tumours, but the tumour suppressor gene targeted by this deletion is unknown. p73 is a novel gene that has high sequence homology and similar gene structure to the p53 gene; it has been mapped to 1 p36, and may thus represent a candidate for this tumour suppressor gene.
|
11461077 |
2001 |
|
Brain Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
The p36 region of chromosome one has been reported to have frequent loss of heterozygosity (LOH) in brain and central nervous system (CNS) tumors and epidemiological studies have shown an increased relative risk of BC and tumors of the CNS in PC families.
|
11536309 |
2001 |
|
Central Nervous System Neoplasms
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The p36 region of chromosome one has been reported to have frequent loss of heterozygosity (LOH) in brain and central nervous system (CNS) tumors and epidemiological studies have shown an increased relative risk of BC and tumors of the CNS in PC families.
|
11536309 |
2001 |
|
Central neuroblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
LOH at 1p36 was found in 24 of 80 cases, suggesting the possibility of a tumor suppressor gene at 1 p36 near the site of a suspected neuroblastoma tumor suppressor gene.
|
10616197 |
1999 |
|
Central neuroblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Cytogenetic and molecular studies in neuroblastoma suggest the presence of a tumor suppressor gene at the distal band p36 of human chromosome 1.
|
7700633 |
1995 |
|
Childhood Neuroblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Cytogenetic and molecular studies in neuroblastoma suggest the presence of a tumor suppressor gene at the distal band p36 of human chromosome 1.
|
7700633 |
1995 |
|
Childhood Neuroblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
LOH at 1p36 was found in 24 of 80 cases, suggesting the possibility of a tumor suppressor gene at 1 p36 near the site of a suspected neuroblastoma tumor suppressor gene.
|
10616197 |
1999 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Comparative genomic hybridization analysis identifies gains of 1p35 approximately p36 and chromosome 19 in osteosarcoma.
|
11672768 |
2001 |
|
Crohn Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
The reactivity of anti-M. paratuberculosis (specifically against p35 and p36 antigens) antibodies in a significant proportion of CD patients would suggest a causal role for the organism in CD.
|
11118734 |
2000 |
|
Crohn Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
The fact that sera from Crohn's disease patients reacted to p36 with the same high frequency as the sera from patients that were exposed to mycobacterial antigens further supports the hypothesis of the mycobacterial etiology in Crohn's disease.
|
10398839 |
1999 |
|
Diabetes
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition to the documented effect of diabetes to increase p36 mRNA and protein in the liver and kidney, a approximately 2-fold increase in the mRNA abundance of p46 was found in liver, kidney, and intestine, and a similar increase was found in the p46 protein level in liver.
|
10567346 |
1999 |
|
Diabetes Mellitus
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In addition to the documented effect of diabetes to increase p36 mRNA and protein in the liver and kidney, a approximately 2-fold increase in the mRNA abundance of p46 was found in liver, kidney, and intestine, and a similar increase was found in the p46 protein level in liver.
|
10567346 |
1999 |
|
Ductal Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In CGH analysis, the patients showed typical imbalances for ductal breast cancer: gains of 1q (3 patients), 5q (2 patients), 8q (3 patients), and X (4 patients) and losses of 1p33 approximately p36 (3 patients), 16q (3 patients), 17p (3 patients), 19 (4 patients), and 22q (4 patients).
|
14553951 |
2003 |
|
Gerstmann-Straussler-Scheinker Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Mutations in P36 and P46 lead to glycogen storage disease (GSD) type-1a and type-1 non a (formerly 1b and 1c), respectively.
|
10712583 |
2000 |
|
Glycogen Storage Disease
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Mutations in P36 and P46 lead to glycogen storage disease (GSD) type-1a and type-1 non a (formerly 1b and 1c), respectively.
|
10712583 |
2000 |
|
Harlequin Fetus
|
0.010 |
Biomarker
|
disease |
BEFREE |
In female mice, HI injury prolonged the time spent at the periphery (open field) at p36 (p = 0.004), regardless of treatment.
|
28196356 |
2017 |
|
Inflammatory Bowel Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Sera from 77 of 89 (86.5%) Crohn's disease patients and 16 of 18 (89%) sera from patients with tuberculosis and leprosy reacted with p36 compared to 5 of 42 (12%) ulcerative colitis and non-IBD control sera (p < 0.0001).
|
10398839 |
1999 |
|
Leprosy
|
0.010 |
Biomarker
|
disease |
BEFREE |
All seven sarcoidosis, four of six tuberculosis, and all six leprosy patient serum specimens showed strong reactivity with p36 antigen.
|
8862592 |
1996 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
The presence of 1p abnormalities in AML and other malignancies is reviewed, as are candidate tumor suppressor genes in the 1p34 approximately p36 region.
|
12547161 |
2002 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two T cell lines specific to two dominant CTL epitopes derived from JCV VP1 protein (termed p36 and p100) from an HLA-A0201+ PML survivor were generated for TCR cloning.
|
17660502 |
2007 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
A 960-base-pair cDNA was isolated and found to be a partial cDNA encoding the human protein-tyrosine kinase substrate p36, also known as lipocortin II. p36 expression was highly abundant in hepatocellular carcinomas at both the transcript and protein levels.
|
2160596 |
1990 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These investigations explored the effect of ethanol additions on the expression and tyrosyl phosphorylation (TP) of p36 and IRS-1 in a human hepatocellular carcinoma cell line (FOCUS) in relationship to cell proliferation induced by IN and serum growth factor stimulation.
|
7542850 |
1995 |
|
Lupus Erythematosus
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results show that p36 is a new interferon-alpha-induced protein that localizes in the endoplasmic reticulum, the cell region in which the lupus inclusions form, and that p36 is probably physically associated with the lupus inclusions.
|
8557639 |
1996 |